{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.76","value":"30.3"},{"groupId":"OG001","spread":"22.97","value":"29.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"352"},{"groupId":"OG001","value":"350"}],"units":"Participants"}],"title":"Disease Symptoms: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.74","value":"-3.1"},{"groupId":"OG001","spread":"22.44","value":"-5.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"215"}],"units":"Participants"}],"title":"Disease Symptoms: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.53","value":"18.0"},{"groupId":"OG001","spread":"15.04","value":"17.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"352"},{"groupId":"OG001","value":"350"}],"units":"Participants"}],"title":"Side-Effects: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.52","value":"1.7"},{"groupId":"OG001","spread":"15.91","value":"3.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"214"}],"units":"Participants"}],"title":"Side-Effects: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.67","value":"81.7"},{"groupId":"OG001","spread":"29.11","value":"81.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"346"},{"groupId":"OG001","value":"346"}],"units":"Participants"}],"title":"Body Image: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.93","value":"-7.8"},{"groupId":"OG001","spread":"29.66","value":"-2.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"207"}],"units":"Participants"}],"title":"Body Image: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.95","value":"57.3"},{"groupId":"OG001","spread":"28.47","value":"55.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"350"},{"groupId":"OG001","value":"349"}],"units":"Participants"}],"title":"Future Perspective: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.85","value":"4.4"},{"groupId":"OG001","spread":"25.69","value":"6.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"211"}],"units":"Participants"}],"title":"Future Perspective: End of Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"352"},{"groupId":"OG001","value":"350"}],"units":"Participants"}],"description":"EORTC QLQ-MY20 was a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. The scale has 20 questions. Subscale and individual items include future perspective items 18-20, body image item 17, disease symptoms items 1-6, side effects of treatment items 7-16. Raw scores are averaged, and transformed to 0-100 scale, where higher score is better quality of life. Positive change indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Participants who were randomly assigned to receive placebo matching capsule single oral dose on Days 1, 8 and 15 along with standard regimen of LenDex (lenalidomide 25 mg capsules orally on Days 1-21 and dexamethasone 40 mg tablets orally on Days 1, 8, 15 and 22) for the first 18 cycles (each cycle was of 28 days). Following Cycle 18, participants received 3.0 mg ixazomib matching placebo capsule as single oral dose on Days 1, 8 and 15 along with lenalidomide 10 mg capsules orally on Days 1-21 in each 28-day cycle until progressive disease or unacceptable toxicity, whichever comes first up to end of study (up to approximately 109 months).","id":"OG000","title":"Placebo + LenDex"},{"description":"Participants who were randomly assigned to receive Ixazomib 4.0 mg capsule single oral dose on Days 1, 8 and 15 along with standard regimen of LenDex (lenalidomide 25 mg capsules orally on Days 1-21 and dexamethasone 40 mg tablets orally on Days 1, 8, 15 and 22) for the first 18 cycles (each cycle was of 28 days). Following Cycle 18, participants received 3.0 mg ixazomib capsule as single oral dose on Days 1, 8 and 15 along with lenalidomide 10 mg capsules orally on Days 1-21 in each 28-day cycle until progressive disease or unacceptable toxicity, whichever comes first up to end of study (up to approximately 109 months).","id":"OG001","title":"Ixazomib + LenDex"}],"paramType":"MEAN","populationDescription":"ITT population included all participants who were randomized. Overall number of participants analyzed is the number of participants available for analyses. Number analyzed indicates the number of participants available for analysis at the given timepoint.","reportingStatus":"POSTED","timeFrame":"Baseline to approximately 9 years","title":"Change From Baseline in HRQOL Measured by EORTC-QLQ-MY20 Scale","type":"SECONDARY","unitOfMeasure":"score on a scale"}